Alvotech ( (ALVO) ) has provided an update.
On February 21, 2025, Alvotech announced the U.S. availability of SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara®, following FDA approval in October 2024. This launch marks the second biosimilar released under the Alvotech and Teva partnership, aimed at providing cost-effective treatment options for conditions like psoriasis and Crohn’s disease. The FDA has provisionally determined SELARSDI to be interchangeable with Stelara®, enhancing its market potential and reinforcing the partnership’s commitment to affordable healthcare solutions.
More about Alvotech
Alvotech is a company operating in the biopharmaceutical industry, focusing on the development and manufacturing of biosimilar products. The company has a strategic partnership with Teva Pharmaceuticals to commercialize biosimilars in the U.S. market, leveraging Teva’s extensive sales and marketing infrastructure.
YTD Price Performance: -6.69%
Average Trading Volume: 159,751
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $3.7B
Learn more about ALVO stock on TipRanks’ Stock Analysis page.